Patheon and Senopsys Announce Alliance
Patheon and Senopsys LLC have formed an alliance to develop dose formulations which enhance palatability (taste) for drugs that are in development. The alliance between Patheon and Senopsys is intended to deliver patient accepted pediatric formulations, line extension products and reformulated pharmaceutical products. These products will be optimized for palatability to increase patient compliance and improve health outcomes. Products with enhanced sensory characteristics such as smell, taste, texture, mouthfeel and appearance, ultimately can have a dramatic effect on whether a patient consistently adheres to the required dosing regimen.
Wes Wheeler, Patheon's CEO stated, "By creating this alliance with Senopsys, both companies can combine the proven history of Patheon's experience in formulation development and quality with Senopsys' expertise in taste assessment and optimization. The unique combination of innovative formulation and taste masking allows us to offer customers the potential to meet regulatory requirements and extend the patent life of their new drugs by six months."
Other news from the department business & finance
